Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Medical Imaging
  4. Fast Track Articles
  5. Fast Track Article
image of Exploring the Prevalence and Coexistence of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes Mellitus Patients Using Ultrasound: A Cross-sectional Study
file format pdf download PDF

Abstract

Background:

Type 2 diabetes Mellitus (T2DM) increases vulnerability to metabolic dysfunction-associated steatotic liver disease (MASLD). Therefore, this study aims to determine the prevalence and coexistence of MASLD in patients with T2DM using ultrasound.

Methods:

This cross-sectional retrospective study included 168 patients with T2DM from multiple diabetes clinics in Abha City, Asir region, recruited between August 2023 and December 2023. Adult patients aged 18 and over with T2DM were included, and data was extracted from patient files. All patients were examined by ultrasound to determine the prevalence and coexistence of MASLD in patients with T2DM. Hepatic steatosis on B-mode ultrasound is qualitatively classified on a four-point scale: normal (0), mild (1), moderate (2), and severe (3).

Results:

Out of 168 patients, 68.4% were identified with MASLD, mostly with diffuse liver (97.4%) diagnosed through ultrasound. MASLD was significantly higher in individuals with uncontrolled diabetes (72.5%) than those with controlled diabetes (46.2%), with a significant difference (=0.015) and an odds ratio (OR) of 3.081, indicating uncontrolled diabetics are over three times more likely to develop MASLD. The uncontrolled group had a statistically significant larger liver size than the control group (13.6cm ±1.43 . 13.0cm ±1.20, respectively: [=0.032, 95%CI 0.053-1.12]). Furthermore, a notable association was observed between increased BMI and the prevalence of MASLD in individuals with T2DM. Furthermore, no significant association was found between the duration of diabetes and the severity of MASLD, nor between the grading of MASLD and gender.

Conclusion:

This study highlights a crucial association between uncontrolled diabetes and increased MASLD prevalence, emphasizing the importance of diabetes management in reducing MASLD risk.

© 2024 The Author(s). Published by Bentham Science.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cmir/10.2174/0115734056354807241217043210
2025-01-02
2025-01-18

  • From This Site

    /content/journals/cmir/10.2174/0115734056354807241217043210
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmir/10.2174/0115734056354807241217043210/e15734056354807.html?itemId=/content/journals/cmir/10.2174/0115734056354807241217043210&mimeType=html&fmt=ahah

References

  1. Rinella M.E. Lazarus J.V. Ratziu V. Francque S.M. Sanyal A.J. Kanwal F. Romero D. Abdelmalek M.F. Anstee Q.M. Arab J.P. Arrese M. Bataller R. Beuers U. Boursier J. Bugianesi E. Byrne C.D. Castro Narro G.E. Chowdhury A. Cortez-Pinto H. Cryer D.R. Cusi K. El-Kassas M. Klein S. Eskridge W. Fan J. Gawrieh S. Guy C.D. Harrison S.A. Kim S.U. Koot B.G. Korenjak M. Kowdley K.V. Lacaille F. Loomba R. Mitchell-Thain R. Morgan T.R. Powell E.E. Roden M. Romero-Gómez M. Silva M. Singh S.P. Sookoian S.C. Spearman C.W. Tiniakos D. Valenti L. Vos M.B. Wong V.W.S. Xanthakos S. Yilmaz Y. Younossi Z. Hobbs A. Villota-Rivas M. Newsome P.N. NAFLD Nomenclature consensus group A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023 78 6 1966 1986 10.1097/HEP.0000000000000520 37363821
    [Google Scholar]
  2. Loomba R. Friedman S.L. Shulman G.I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021 184 10 2537 2564 10.1016/j.cell.2021.04.015 33989548
    [Google Scholar]
  3. Younossi Z.M. Golabi P. de Avila L. Paik J.M. Srishord M. Fukui N. Qiu Y. Burns L. Afendy A. Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J. Hepatol. 2019 71 4 793 801 10.1016/j.jhep.2019.06.021 31279902
    [Google Scholar]
  4. Kleiner D.E. Brunt E.M. Van Natta M. Behling C. Contos M.J. Cummings O.W. Ferrell L.D. Liu Y.C. Torbenson M.S. Unalp-Arida A. Yeh M. McCullough A.J. Sanyal A.J. Nonalcoholic Steatohepatitis Clinical Research Network Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 41 6 1313 1321 10.1002/hep.20701 15915461
    [Google Scholar]
  5. Dharmalingam M. Yamasandhi P.G. Nonalcoholic fatty liver disease and Type 2 diabetes mellitus. Indian J. Endocrinol. Metab. 2018 22 3 421 428 10.4103/ijem.IJEM_585_17 30090738
    [Google Scholar]
  6. Anstee Q.M. McPherson S. Day C.P. How big a problem is non-alcoholic fatty liver disease? BMJ 2011 343 jul18 1 d3897 10.1136/bmj.d3897 21768191
    [Google Scholar]
  7. Wong W.K. Chan W.K. Nonalcoholic fatty liver disease: A global perspective. Clin. Ther. 2021 43 3 473 499 10.1016/j.clinthera.2021.01.007 33526312
    [Google Scholar]
  8. Younossi Z.M. Non-alcoholic fatty liver disease – A global public health perspective. J. Hepatol. 2019 70 3 531 544 10.1016/j.jhep.2018.10.033 30414863
    [Google Scholar]
  9. Asrani S.K. Devarbhavi H. Eaton J. Kamath P.S. Burden of liver diseases in the world. J. Hepatol. 2019 70 1 151 171 10.1016/j.jhep.2018.09.014 30266282
    [Google Scholar]
  10. Kanwal F. Shubrook J.H. Adams L.A. Pfotenhauer K. Wai-Sun Wong V. Wright E. Abdelmalek M.F. Harrison S.A. Loomba R. Mantzoros C.S. Bugianesi E. Eckel R.H. Kaplan L.M. El-Serag H.B. Cusi K. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 2021 161 5 1657 1669 10.1053/j.gastro.2021.07.049 34602251
    [Google Scholar]
  11. Khalifa A. Rockey D.C. The utility of liver biopsy in 2020. Curr. Opin. Gastroenterol. 2020 36 3 184 191 10.1097/MOG.0000000000000621 32097176
    [Google Scholar]
  12. Rockey D.C. Caldwell S.H. Goodman Z.D. Nelson R.C. Smith A.D. American Association for the Study of Liver Diseases Liver biopsy. Hepatology 2009 49 3 1017 1044 10.1002/hep.22742 19243014
    [Google Scholar]
  13. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) (EASD. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes. Facts 2016 9 2 65 90 10.1159/000443344 27055256
    [Google Scholar]
  14. Hernaez R. Lazo M. Bonekamp S. Kamel I. Brancati F.L. Guallar E. Clark J.M. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology 2011 54 3 1082 1090 10.1002/hep.24452 21618575
    [Google Scholar]
  15. Petzold G. Role of ultrasound methods for the assessment of NAFLD. J. Clin. Med. 2022 11 15 4581 10.3390/jcm11154581 35956196
    [Google Scholar]
  16. Sberna A.L. Bouillet B. Rouland A. Brindisi M.C. Nguyen A. Mouillot T. Duvillard L. Denimal D. Loffroy R. Vergès B. Hillon P. Petit J.M. European association for the study of the liver ( EASL ), european association for the study of diabetes ( EASD ) and european association for the study of obesity ( EASO ) clinical practice recommendations for the management of non‐alcoholic fatty liver disease: Evaluation of their application in people with type 2 diabetes. Diabet. Med. 2018 35 3 368 375 10.1111/dme.13565 29247558
    [Google Scholar]
  17. Kosmalski M. Ziółkowska S. Czarny P. Szemraj J. Pietras T. The coexistence of nonalcoholic fatty liver disease and type 2 diabetes mellitus. J. Clin. Med. 2022 11 5 1375 10.3390/jcm11051375 35268466
    [Google Scholar]
  18. Ciardullo S. Vergani M. Perseghin G. Nonalcoholic fatty liver disease in patients with type 2 diabetes: Screening, diagnosis, and treatment. J. Clin. Med. 2023 12 17 5597 10.3390/jcm12175597 37685664
    [Google Scholar]
  19. van Werven J.R. Marsman H.A. Nederveen A.J. Smits N.J. ten Kate F.J. van Gulik T.M. Stoker J. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology 2010 256 1 159 168 10.1148/radiol.10091790 20574093
    [Google Scholar]
  20. Mitra S. De A. Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl. Gastroenterol. Hepatol. 2020 5 16 10.21037/tgh.2019.09.08 32258520
    [Google Scholar]
  21. Portillo-Sanchez P. Bril F. Maximos M. Lomonaco R. Biernacki D. Orsak B. Subbarayan S. Webb A. Hecht J. Cusi K. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J. Clin. Endocrinol. Metab. 2015 100 6 2231 2238 10.1210/jc.2015‑1966 25885947
    [Google Scholar]
  22. Fan N. Zhang L. Xia Z. Peng L. Wang Y. Peng Y. Sex‐specific association between serum uric acid and nonalcoholic fatty liver disease in type 2 diabetic patients. J. Diabetes Res. 2016 2016 1 1 6 10.1155/2016/3805372 27382573
    [Google Scholar]
  23. Guo K. Zhang L. Lu J. Yu H. Wu M. Bao Y. Chen H. Jia W. Non-alcoholic fatty liver disease is associated with late but not early atherosclerotic lesions in Chinese inpatients with type 2 diabetes. J. Diabetes Complications 2017 31 1 80 85 10.1016/j.jdiacomp.2016.09.008 27742552
    [Google Scholar]
  24. Yi M. Chen R.P. Yang R. Chen H. Increased prevalence and risk of non‐alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China. Diabet. Med. 2017 34 4 505 513 10.1111/dme.13174 27334577
    [Google Scholar]
  25. Sima A. Timar R. Vlad A. Timar B. Rosu M. Dan I. Sirli R. Popescu A. Sporea I. Nonalcoholic fatty liver disease: A frequent condition in type 2 diabetic patients. Wien. Klin. Wochenschr. 2014 126 11-12 335 340 10.1007/s00508‑014‑0530‑8 24652019
    [Google Scholar]
  26. Rashid A. Zafar S. Bashir A. Bakht K. Bhalli A.U. Presence of non-alcoholic fatty liver disease in patients of uncontrolled and controlled type 2 diabetes mellitus. Pak. Armed Forces Med. J. 2019 69 4 822 825
    [Google Scholar]
  27. Moon S.S. Relationship between serum uric acid level and nonalcoholic fatty liver disease in pre- and postmenopausal women. Ann. Nutr. Metab. 2013 62 2 158 163 10.1159/000346202 23406781
    [Google Scholar]
  28. Kwon YM Oh SW Hwang SS Lee C Kwon H Chung GE Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am. J. Gastroenterol. 2012 107 12 1852 1858 10.1038/ajg.2012.314
    [Google Scholar]
  29. Ali A. Amin M.J. Ahmed M.U. Taj A. Aasim M. Tabrez E. Frequency of non-alcoholic fatty liver disease (NAFLD) and its associated risk factors among Type-2 diabetics. Pak. J. Med. Sci. 2022 38 1 28 33 35035396
    [Google Scholar]
  30. McPherson S. Hardy T. Henderson E. Burt A.D. Day C.P. Anstee Q.M. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J. Hepatol. 2015 62 5 1148 1155 10.1016/j.jhep.2014.11.034 25477264
    [Google Scholar]
  31. Pais R. Charlotte F. Fedchuk L. Bedossa P. Lebray P. Poynard T. Ratziu V. LIDO Study Group A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J. Hepatol. 2013 59 3 550 556 10.1016/j.jhep.2013.04.027 23665288
    [Google Scholar]
  32. Patel H. Verma Y.N. Prevalence of non-alcoholic fatty liver disease in type-2 diabetes mellitus patients. Int. J. Res. Med. Sci. 2018 6 4 1322 1326 10.18203/2320‑6012.ijrms20181290
    [Google Scholar]
  33. Lv W.S. Sun R.X. Gao Y.Y. Wen J.P. Pan R.F. Li L. Wang J. Xian Y.X. Cao C.X. Zheng M. Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes. World J. Gastroenterol. 2013 19 20 3134 3142 10.3748/wjg.v19.i20.3134 23716995
    [Google Scholar]
  34. Williamson R.M. Price J.F. Glancy S. Perry E. Nee L.D. Hayes P.C. Frier B.M. Van Look L.A.F. Johnston G.I. Reynolds R.M. Strachan M.W.J. Edinburgh Type 2 Diabetes Study Investigators Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: The edinburgh type 2 diabetes study. Diabetes Care 2011 34 5 1139 1144 10.2337/dc10‑2229 21478462
    [Google Scholar]
/content/journals/cmir/10.2174/0115734056354807241217043210
Loading
Exploring the Prevalence and Coexistence of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes Mellitus Patients Using Ultrasound: A Cross-sectional Study
Bentham Science Publishers , e15734056354807; https://doi.org/10.2174/0115734056354807241217043210
/content/journals/cmir/10.2174/0115734056354807241217043210
/content/journals/cmir/10.2174/0115734056354807241217043210
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Controlled diabetes ; Uncontrolled diabetes ; Type 2 diabetic mellitus ; MASLD ; BMI ; Ultrasound

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test